CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology , Beijing 100190, China.
Royal Brisbane Hospital, QIMR Berghofer Medical Research Institute , Brisbane 4029, QLD, Australia.
ACS Appl Mater Interfaces. 2018 Feb 28;10(8):6972-6981. doi: 10.1021/acsami.7b19258. Epub 2018 Feb 19.
Although postsurgical chemotherapy is frequently used for the treatment of breast cancer, tumor recurrence is still a frequent event. Enhancing the efficacy of chemotherapy via localized drug delivery may help to prevent breast cancer recurrence. To achieve this goal, we designed a hydrogel nanocarrier that could be injected at the tumor site by coassembly of tailor-made hexapeptide and doxorubicin. Evidently, on the basis of our findings, the sustained release of drug from the hydrogel led to a reduction in cancer recurrence, including the suppression of primary regrowth and distant metastasis. This localized chemotherapy strategy did not show any obvious side effects in vivo and represents a promising adjuvant therapeutic strategy for breast cancer recurrence.
尽管术后化疗常用于治疗乳腺癌，但肿瘤复发仍然是一个常见事件。通过局部药物递送增强化疗的疗效可能有助于预防乳腺癌复发。为了实现这一目标，我们设计了一种水凝胶纳米载体，它可以通过定制六肽和阿霉素的共组装在肿瘤部位注射。显然，根据我们的研究结果，药物从水凝胶中的持续释放导致癌症复发的减少，包括原发性再生长和远处转移的抑制。这种局部化疗策略在体内没有显示出任何明显的副作用，是一种有前途的乳腺癌复发辅助治疗策略。
